Emily Friedland
About Emily Friedland
Emily Friedland: VP of Clinical Research
Emily Friedland holds the position of Vice President of Clinical Research. In this role, she oversees the clinical research initiatives within the organization, ensuring that all clinical trials and studies adhere to regulatory standards and scientific rigor. Her leadership is pivotal in the development, implementation, and management of clinical research projects. She plays a crucial role in guiding the strategic direction of the clinical research department and ensuring alignment with the organization’s goals.
Emily Friedland: Expert in FDA IVD Reclassification
Emily Friedland is an acknowledged expert in the field of regulatory changes, particularly concerning the FDA's in vitro diagnostic (IVD) reclassification. She has authored an article titled 'New Rules, New Approaches: Understanding the FDA’s IVD Reclassification Impact,' which examines the implications of these regulatory changes. The article provides insights into how the new rules affect clinical research and the strategies required to adapt to these changes. Through her work, Emily demonstrates a deep understanding of regulatory environments and their impacts on clinical practices.